Clinical trials: End-of-Life
Sudden Cardiac Death, Sudden Cardiac Arrest
Time and Dose Evaluation of Stearidonic Acid (SDA) to Eicosapentaenoic Acid (EPA) in Red Blood Cells
The purpose of this study is to assess the relationships between dose and time of consumption of stearidonic acid (SDA) and eicosapentaenoic acid (EPA) on EPA enrichment of red blood cell (RBC) membranes in men and women.
- Conditions
- Sudden Cardiac Death, Sudden Cardiac Arrest, Cardiovascular Disease
- Trial name
- NK (NCT01038440)
- Testing
- Safflower Oil, EPA, SDA
- Volunteers
- 137 people, healthy volunteers welcome
- Sponsor
- Solae, LLC
Cardiopulmonary Failure, Myocardial Infarction (MI)
COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable
The COR-INSIGHT trial aims to evaluate the effectiveness of Peerbridge COR advanced ambulatory ECG wearables (COR 1.0 and COR 2.0) in accurately and non-invasively detecting cardiovascular and cardiopulmonary conditions using…
- Conditions
- Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure
- Trial name
- COR-INSIGHT (NCT06763549)
- Testing
- SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C
- Where
- United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
End Stage Renal Disease
Quality of Life on Peritoneal Dialysis Versus Hemodialysis in China
This is a multicenter, randomized, open-label study to compare QoL in subjects with end-stage renal disease (ESRD) requiring PD or conventional in-center HD treatment.
- Trial name
- NCT02378350
- Testing
- Hemodialysis treatment (no specific device is defined), Peritoneal Dialysis treatment (no specific drug is defined)
- Where
- 21 sites in China
- Volunteers
- 668 people
- Sponsor
- Vantive Health LLC
Urothelial Carcinoma
QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with urothelial cancer who have progressed on or after chemotherapy and anti- PD-1/PD-L1 therapy.
- Trial name
- NCT03197571
- Testing
- avelumab, bevacizumab, capecitabine
- Sponsor
- ImmunityBio, Inc.
Carcinoma, Hepatocellular
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic…
- Trial name
- NCT04246177
- Testing
- Lenvatinib, Pembrolizumab, TACE
- Where
- 205 sites in United States, Australia and 25 more
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Ventricular Tachycardia, Cardiovascular Diseases
Genetic Substudy of the Alternans Before Cardioverter Defibrillator (ABCD) Trial
The ABCD clinical study (ClinicalTrials.gov Identifier NCT00187291) was designed to determine if a T-Wave Alternans (TWA) test is equivalent to an Electrophysiology Study (EPS) in predicting life-threatening heart rhythms in…
- Conditions
- Ventricular Tachycardia, Cardiovascular Diseases, Arrythmia, CVD
- Trial name
- ABCD (NCT00583297)
- Where
- United States
- Volunteers
- 400 people
- Sponsor
- CardioDx
Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma, Sarcoma
Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma
This phase 1/2, multicenter, randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy and safety of AMG 655 when combined with doxorubicin compared with doxorubicin alone in subjects with previously…
- Conditions
- Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma, Sarcoma, Soft Tissue Sarcoma
- Trial name
- NCT00626704
- Testing
- AMG 655, Doxorubicin
- Volunteers
- 134 people
- Sponsor
- Amgen
Liver Transplant Surgery, Liver Transplantation
Open Label Trial of Deceased Donor Livers Transplanted After DHOPE With eXVIVO LIVER Perfusion
The purpose of this clinical study is to confirm the safety and effectiveness of dual hypothermic oxygenated perfusion (DHOPE) using the Liver Assist to preserve deceased donor livers for transplantation.
- Trial name
- NCT06916325
- Testing
- dual hypothermic oxygenated perfusion (DHOPE)
- Volunteers
- 215 people
- Sponsor
- XVIVO Perfusion
Advanced Solid Tumors
Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)
This study will assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of escalating doses of quavonlimab when used in combination with pembrolizumab in participants with advanced solid tumors.
- Trial name
- NCT03179436
- Testing
- Quavonlimab, Pembrolizumab, Pembrolizumab/Quavonlimab
- Where
- 53 sites in United States, Australia and 14 more
- Volunteers
- 415 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometrial Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent.
- Trial name
- TroFuse-033 (NCT06952504)
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 268 sites in United States, Argentina and 32 more
- Volunteers
- 1,123 people
- Sponsor
- Merck Sharp & Dohme LLC
Head and Neck Neoplasms
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)
The purpose of this study is to determine the efficacy and safety of pembrolizumab given concomitantly with chemoradiation (CRT) and as maintenance therapy versus placebo plus CRT in participants with locally advanced head and…
- Trial name
- NCT03040999
- Testing
- Pembrolizumab, Cisplatin, Accelerated Fractionation (AFX) Radiotherapy
- Where
- 151 sites in United States, Australia and 19 more
- Volunteers
- 804 people
- Sponsor
- Merck Sharp & Dohme LLC
Esophageal Neoplasms
First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)
The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus standard of care (SOC) chemotherapy with cisplatin and 5-fluorouracil (5-FU) versus placebo plus SOC chemotherapy with cisplatin and 5-FU as…
- Trial name
- NCT03189719
- Testing
- Pembrolizumab, Cisplatin, 5-FU
- Where
- 189 sites in United States, Argentina and 24 more
- Volunteers
- 749 people
- Sponsor
- Merck Sharp & Dohme LLC
Delayed Graft Function
Study on Delayed Graft Function Using Paired Kidneys
The study is designed to evaluate the safety and efficacy of an intravenously administered drug in recipients of kidneys from cardiac death donors who are risk for developing delayed graft function.
- Trial name
- NCT01561599
- Testing
- BB3, Normal Saline
- Where
- 3 sites in Netherlands, Spain and 1 more
- Volunteers
- 12 people
- Sponsor
- Angion Biomedica Corp
Aging Problems
Enhancing Care of the Aged and Dying in Prisons Ph II
The mission of corrections is to provide custody, control and care for incarcerated individuals. United States prisons are required by constitutional law to provide adequate care for growing numbers of older inmates who will…
- Trial name
- NCT03055429
- Testing
- Full Scale Unit
- Where
- 2 sites in United States
- Volunteers
- 241 people, healthy volunteers welcome
- Sponsor
- Klein Buendel, Inc.
Covid19, Community-Acquired Respiratory Tract Infection
Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19
Solving the problem of detecting asymptomatic carriers who can transmit infection is key to protecting vulnerable residents of nursing homes and assisted living facilities, to protecting frontline workers who care for them, and…
- Trial name
- NCT04548895
- Testing
- Observational measurement of biometric data. No change to health care provided.
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Health Stream Analytics, LLC
Cardiovascular Events, MACE
Tezspire Cardiac Events PASS
The aim of this study is to evaluate the risk of serious adverse cardiovascular events in adolescent and adult patients with severe asthma taking tezepelumab compared to a population receiving standard of care treatment for…
- Trial name
- TRESPASS (NCT06951867)
- Testing
- Tezepelumab
- Where
- 4 sites in United States, Denmark and 2 more
- Volunteers
- 16,640 people
- Sponsor
- AstraZeneca
Birth Asphyxia
Asphyxia Associated Metabolite Biomarker Investigation 2
Follow-up of participants of AAMBI1 study at age of at least 2 years. AAMBI1(ClinicalTrials.gov ID: NCT03354208): Verification of biomarkers in a human population for their ability to diagnose the severity of neonatal asphyxia.
- Trial name
- AAMBI2 (NCT04714502)
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 144 people
- Sponsor
- InfanDx AG
Nasopharyngeal Neoplasms
Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122)
This is a study of pembrolizumab (MK-3475) versus standard treatment (capecitabine, gemcitabine, or docetaxel) for the treatment of recurrent or metastatic nasopharyngeal cancer (NPC).
- Trial name
- NCT02611960
- Testing
- Pembrolizumab, Capecitabine, Gemcitabine
- Volunteers
- 233 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
The purpose of this study is to assess the efficacy of pembrolizumab (MK-3475) versus docetaxel in participants with non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) positive tumors who have…
- Trial name
- NCT02864394
- Testing
- Pembrolizumab, Docetaxel
- Volunteers
- 425 people
- Sponsor
- Merck Sharp & Dohme LLC
Peripheral Artery Disease
A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease
The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.
- Trial name
- EUCLID (NCT01732822)
- Testing
- Ticagrelor, Clopidogrel
- Where
- 776 sites in United States, Argentina and 26 more
- Volunteers
- 13,885 people
- Sponsor
- AstraZeneca